New york citys department of financial services took legal action against Johnson & & Johnson Sept. 17, accusing the drugmaker of misrepresenting opioids in its marketing.
The state declared Johnson & & Johnson fostered a hazardous market for opioids by targeting older clients through sales brochures and third-party publications while downplaying the danger included with opioid treatment for that population, supposed that opioid dependency is a misconception, mischaracterized abuse data to lessen the perceived danger of dependency, and made other unsubstantiated claims.
More short articles on opioids: HHS provides neighborhoods $115M to combat the opioid epidemic in 2020Large United States counties reveal uptick in overdose deathsTaxing drugmakers, distributors for opioid treatment programs promoted by US appeals court.
xing drugmakers, distributors for opioid treatment programs upheld by United States appeals court.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
Katie Adams –
Friday, September 18th, 2020
The drugmaker makes numerous opioid items in the state, most especially the fentanyl spot Duragesic and the Nucynta, its brand of tapentadol. It also handles a significant portion of the raw opioid supply chain, at one point managing approximately 80 percent of oxycodone basic materials international supply.
” The opioid crisis has taken a lot of lives and New York State will continue to do something about it against those who helped sustain this public health disaster and bring a measure of justice to households who have lost loved ones,” Gov. Andrew Cuomo stated in a news release. “Misrepresentation of opioids to consumers for revenue is inexcusable and we will use every tool required to assist make sure those responsible are held fully accountable.”.